Migrasome Therapeutics

What Migrasome Therapeutics does

Migrasome Therapeutics (Beijing Migrasome Biotechnology Co., Ltd.) is a Beijing-based private biotechnology company founded in April 2022 by Professor Li Yu of Tsinghua University to commercialize the biology of migrasomes, a novel class of cell organelles first discovered and named by Yu's laboratory in 2012 and published in 2014. The company operates a dual business model. Its first revenue stream is the sale of research reagent kits under sub-brands including MigraPrep (cultured cell migrasome extraction/purification), MigraIso (human and mouse blood and tissue migrasome kits), MigraSee (a chip-based migrasome quantitation platform), and WGA fluorescent dyes. These kits cover the entire routine migrasome research workflow and are sold directly to academic institutions, clinical laboratories, and pharmaceutical companies through WeChat, email, and the company website.

The company's longer-term, pre-revenue opportunity is the Engineered Migrasome (eMigrasome) drug delivery platform, which the company positions as a novel biological delivery vehicle with high biocompatibility, low toxicity, modifiable surface and cargo, and the potential to traverse complex biological barriers including the blood-brain barrier. Therapeutic programs are aimed at immunology, oncology, and angiogenesis, with the company explicitly pursuing strategic enterprise partnerships — most notably joining the Roche China Accelerator in May 2023 to accelerate migrasome-based drug development. Revenue today is concentrated in low-margin research kit sales, while future economics are expected to derive from licensing, royalties, and co-development deals tied to the proprietary migrasome biology originated by Prof. Li Yu's laboratory.

Name

Migrasome Therapeutics

Legal name

北京迈格松生物科技有限公司

Website

https://migrasome.com

Company type

Private

Founded year

2022

Operating status

Operating

Short description

Migrasome Therapeutics is a Beijing-based biotech founded in 2022 by Professor Li Yu that sells migrasome research reagent kits to academic, clinical, and pharmaceutical customers, while developing an engineered migrasome (eMigrasome) drug delivery platform and therapeutics targeting immunology, oncology, and blood-brain barrier delivery.

Ownership category

akta.pro rank

Product category

Life Science Research Reagents

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Life science reagents
• Drug delivery platforms
• Extracellular vesicle research
• Biotechnology research
• Cell biology products

Headquarters

HQ city

Zijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Research Reagent Kits and Services: Sale of migrasome extraction and purification research kits to academic institutions, research laboratories, and pharmaceutical companies conducting migrasome research. Products include cultured cell migrasome kits, blood migrasome kits, tissue migrasome kits, detection chips, and fluorescent dyes sold in various sizes (5-50 tests). Revenue generated through direct sales with pricing determined by kit size and specifications.
2. Drug Development and Licensing: Development of novel therapeutics based on migrasome biology including drug delivery platforms, disease diagnostics, and migrasome regulatory drugs. Currently pre-revenue with focus on R&D and partnership development for clinical translation.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Migrasome Therapeutics manufactures and sells migrasome research reagent kits (extraction, purification, quantification, and staining products for cultured cells, human/mouse blood, and tissues) and develops an Engineered Migrasome (eMigrasome) drug delivery platform for novel therapeutics in oncology, immunology, and central nervous system indications. The company is the only global commercial entity built on migrasome biology, leveraging proprietary IP derived from Prof. Li Yu's foundational discoveries at Tsinghua University.

Product overview

Migrasome Therapeutics offers a comprehensive portfolio of migrasome research reagent kits and platforms, covering the entire routine migrasome research workflow: observation (MigraSee quantitation platform, WGA dyes), extraction and purification (MigraPrep for cultured cells, MigraIso for blood and tissue samples), and detection/characterization. The portfolio includes kits for human and mouse blood (total cell and neutrophil-specific), cultured cells, and tissue samples, along with a chip-based quantitation platform and fluorescent dyes. The company also develops engineered migrasome drug delivery platforms and migrasome-based disease diagnostics for therapeutic applications.

Differentiator

Problem solved

Functional benefit

Brands

• MigraIso: Migration body extraction and purification kits for blood and tissue samples including human blood total migrasomes, human blood neutrophil migrasomes, and tissue migrasomes
• MigraPrep
• MigraSee
• WGA (Migrasome Dye)

Products and services

• MigraPrep Cultured Cell Migrasomes Kit (MGS-P003) Research reagent kit for extracting and purifying migrasomes from in vitro cultured adherent cells. Suitable for fluorescence staining imaging analysis, flow cytometry, nucleic acid extraction, protein extraction, mass spectrometry, and downstream cell function experiments. Validated for L929-Tspan4, NRK-Tspan4, HEK293T-Tspan4, and primary cells including MGC803, RAW264.7, and various MSCs.
• MigraPrep Turbo Cultured Cell Migrasomes Kit (MGS-P016) Enables rapid production and purification of cultured cell migrasomes without requiring density gradient centrifugation, simplifying the extraction workflow. Available in 50-test (MGS-P016) and 10-test (MGS-P016S) sizes for 150mm culture dishes.
• MigraIso Human Blood Total Migrasomes Kit (MGS-P007) Extracts total immune cell migrasomes from human whole blood samples using specific magnetic beads to remove platelets and other impurities. Compatible with blood samples from 100μL to 50mL. Available in 20-test (MGS-P007) and 5-test (MGS-P007S) sizes.
• MigraIso Human Blood Neutrophil Migrasomes Kit (MGS-P008) Extracts neutrophil-derived migrasomes from human whole blood samples using specific magnetic beads to remove platelets, T/B/NK cells and other immune cell-derived migrasomes. Manual operation takes approximately 40 minutes. Available in 20-test (MGS-P008) and 5-test (MGS-P008S) sizes.
• MigraIso Mouse Blood Total Migrasomes Kit (MGS-P010) Extracts total cell migrasomes from mouse blood samples. Available in 20-test (MGS-P010) and 5-test (MGS-P010S) sizes for 20mL and 5mL plasma respectively.
• MigraIso Mouse Blood Neutrophil Migrasomes Kit (MGS-P012) Extracts neutrophil-derived migrasomes from mouse blood samples. Available in 20-test (MGS-P012) and 5-test (MGS-P012S) sizes.
• MigraIso Tissue Migrasomes Kit (MGS-P014) Extracts and purifies migrasomes from tissue samples using magnetic bead negative selection, significantly simplifying conventional density gradient purification processes. Available in 50-test (MGS-P014) and 10-test (MGS-P014S) sizes per 100μg crude product.
• MigraSee Migrasome/Mesoscale Vesicle Quantitation Platform (MGS-P101) A chip-based platform for counting and quantifying migrasomes and cross-micron scale microparticles. Available as 42 tests per chip (MGS-P101).
• WGA Migrasome Dye (MGS-P009) Wheat germ agglutinin (WGA) fluorescent dye for migrasome labeling and visualization, available in 488, 555, and 647 wavelengths (100μL each: MGS-P009-488, MGS-P009-555, MGS-P009-647).
• Engineered Migrasome (eMigrasome) Drug Delivery Platform An engineered migrasome delivery technology platform developed for pharmaceutical and biotech partners, capable of delivering nucleic acids, proteins, and small molecules with potential to cross biological barriers including the blood-brain barrier. Currently in pre-revenue R&D and partnership development stage.

Quantifiable outcome

• Engineered migrasome platform demonstrated potential in tumor therapy, immune regulation, and angiogenesis applications
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Roche China AcceleratorcoreStrategic or Co-development Partner · 12 May 2023Migrasome Therapeutics joined Roche China Accelerator as a member company to accelerate development of migrasome-based drug delivery platform and novel therapeutics in immunology and oncology. Roche provides support including resources, expertise, and network access to advance migrasome-based drug development programs targeting unmet medical needs.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• BeiGene: BeiGene is a global oncology biotech with strong China roots and significant ex-China commercial reach. It is comparable as a Chinese-founded biotech that scaled from local R&D to global drug development — a relevant strategic benchmark, though it operates at a substantially later stage than Migrasome.
• Bio-Techne: Bio-Techne is a dominant research-reagent supplier (proteins, antibodies, kits) whose catalog overlaps Migrasome's reagent business in cell-biology and extracellular-vesicle workflows. As the established incumbent, it is the primary competitive threat to Migrasome's MigraPrep/MigraIso reagent line.
• WuXi Biologics: WuXi Biologics is a global biologics CDMO and R&D services provider. Comparable as a China-headquartered life-sciences platform that supports therapeutic developers, and a potential partner for manufacturing Migrasome's engineered migrasome products at scale.

Emerging players

• Arcturus Therapeutics: Arcturus develops lipid-mediated delivery systems (including LNP-based modalities) for nucleic-acid therapeutics, including mRNA and RNA-editing payloads. It represents the LNP competitive class that engineered migrasomes must outperform for nucleic-acid delivery.
• Codiak BioSciences: Codiak pioneered engineered exosome therapeutics (engExo) for oncology and immune modulation — directly comparable mechanism category to Migrasome's engineered migrasomes. Its clinical and corporate history (despite restructuring) is a benchmark for exosome-class delivery platforms that Migrasome would also need to clear.
• Capricor Therapeutics: Capricor develops cell-derived extracellular vesicle therapeutics (CAP-1002, exosome programs) for inflammatory and rare-disease indications. Comparable as a vesicle-based therapeutic platform, although Capricor's biology is centered on cardiosphere-derived cells rather than migrasomes.
• Kimera Labs: Kimera Labs focuses on exosome-based research reagents and cell-free regenerative products, providing another reference point for the vesicle-reagent business model that Migrasome's MigraPrep/MigraIso kits operate in.

Direct peers

• Evox Therapeutics: Evox is engineering exosomes (a related class of extracellular vesicles) as targeted drug-delivery vehicles for nucleic acids and proteins. It is the closest conceptual analog to Migrasome's engineered migrasome platform and competes for similar pharma partnerships and BBB-penetration use cases.

Regional players

• Junshi Biosciences: Junshi is a leading Chinese innovative biotech with a pipeline in oncology and immunology and established pharma collaborations (including with Roche). Comparable as a China-rooted biotech that has leveraged strategic pharma partnerships to advance novel modalities, a trajectory Migrasome aspires to.
• Sino Biological: Sino Biological is a leading China-based reagent supplier for recombinant proteins, antibodies, and research kits. As a regional incumbent, it competes for the same Chinese academic and biotech reagent customers that Migrasome serves via WeChat and direct email.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Migrasome Therapeutics